Healthcare rationing in the Netherlands: The need for specific guidelines

Medical Journal of Australia

Volumn 172, Issue 7, 2000, Pages 329-331

  Mulder, Jannes H ^a,b  

^a Ministry of Health Welfare and Sport Netherlands   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PRAVASTATIN; RIVASTIGMINE;

ALZHEIMER DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTHERMIC THERAPY; NETHERLANDS; PRACTICE GUIDELINE; REVIEW;

EID: 0034599857     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2000.tb123980.x     Document Type: Review

References (12)

1. Vademecum of Health Statistics of the Netherlands 1998. The Hague: Ministry of Health, Welfare and Sports, 1998
2. Government Committee on Choices in Health Care. Choices in health care. Rijswijk: Ministry of Welfare, Health and Cultural Affairs, 1992.
3. Klein R. Priorities and rationing: pragmatism or principles? Time for Britain to follow the Netherlands, New Zealand, and Sweden's lead and get serious. BMJ 1995; 311: 761-762.
4. van der Grinten TED, Kasdorp JP. Choices in Dutch health care; mixing strategies and responsibilities. Health Policy 1999; 50; 105-122
5. Borst-Eilers E. Medical technology assessment and efficiency in health care. Rijswijk: Ministry of Health, Welfare and Sport, 1996.
6. Ham H. Priority setting in health care: learning from international experience. Health Policy 1997; 42: 49-66.
7. Elsinga E, Rutten FFH. Economic evaluation in support of national health policy: the case of the Netherlands Soc Sci Med 1997; 45: 605-620.
8. Rutten FFH, van der Linden JW. Integration of economic appraisal and health care policy in a health insurance system; the Dutch case. Soc Sci Med 1994; 38: 1609-1614.
9. Rutten FFH. Economic evaluation and health care decision-making. Health Policy 1996; 36: 215-229.
10. Lenaghan J. Central government should have a greater role in rationing decisions. BMJ 1997; 314: 967-970.
11. Foy R, So J, Rous E, et al. Perspectives of commissioners and cancer specialists in prioritizing new cancer drugs: impact of the evidence threshold. BMJ 1999; 318: 456-459.
12. Tengs TO, Adams ME, Pliskin JS, et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369-390.